This article was originally published in SRA
Stronger warning for Ketek in the EU
You may also be interested in...
Despite turnover dropping by over a fifth in its financial third quarter, Lannett says it is optimistic that respiratory generics and insulins will offer the firm “durable” opportunities in future. The company has also just reorganized its finances to extend its debt maturity by four years, pushing it back past some of its key launches.
Genomma Lab reports OTC sales rise in Q1 thanks to gains in its LATAM region, while Brazil's Hypera posts big jump in turnover due to acquisitions.
Executive reshuffle at Karyopharm Therapeutics, plus new chief financial officers at Redx Pharma and Vaccibody.